Estimating long COVID-19 prevalence across definitions and forms of sample selection.

Frontiers in epidemiology Pub Date : 2025-05-30 eCollection Date: 2025-01-01 DOI:10.3389/fepid.2025.1597799
Pietro Giorgio Lovaglio, Fabio Borgonovo, Alessandro Manzo Margiotta, Mohamed Mowafy, Marta Colaneri, Alessandra Bandera, Andrea Gori, Amedeo Ferdinando Capetti
{"title":"Estimating long COVID-19 prevalence across definitions and forms of sample selection.","authors":"Pietro Giorgio Lovaglio, Fabio Borgonovo, Alessandro Manzo Margiotta, Mohamed Mowafy, Marta Colaneri, Alessandra Bandera, Andrea Gori, Amedeo Ferdinando Capetti","doi":"10.3389/fepid.2025.1597799","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Long COVID (LC) is a multisystem condition with prolonged symptoms persisting beyond acute SARS-CoV-2 infection. However, prevalence estimates vary widely due to differences in case definitions and sampling methodologies. This study aims to determine the prevalence of LC across different definitions and correct for selection bias using advanced statistical modeling.</p><p><strong>Methods: </strong>We conducted a retrospective, observational study at Luigi Sacco Hospital (Milan, Italy), analyzing 3,344 COVID-19 patients from two pandemic waves (2020-2021). Participants included 1,537 outpatients from the ARCOVID clinic and 1,807 hospitalized patients. LC was defined based on WHO and NICE criteria, as well as two alternative definitions: symptoms persisting at 3 and 6 months post-infection. We used a bivariate censored Probit model to account for selection bias and estimate adjusted LC prevalence.</p><p><strong>Results: </strong>LC prevalence varied across definitions: 67.4% (WHO), 76.3% (NICE), 80.2% (3 months), and 79.6% (6 months). Adjusted prevalence estimates remained consistent across definitions. The most common symptoms were fatigue (58.6%), dyspnea (41.1%), and joint/muscle pain (39.2%). Risk factors included female sex (OR 2.165-2.379), metabolic disease (OR 1.587-1.629), and older age (40-50 years, OR 1.847). Protective factors included antiplatelets (OR 0.640-0.689), statins (OR 0.616), and hypoglycemics (OR 0.593-0.706). Vaccination, hydroxychloroquine, and antibiotics were associated with an increased risk of LC. Selection bias significantly influenced prevalence estimates, underscoring the need for robust statistical adjustments.</p><p><strong>Discussion: </strong>Our findings highlight the high prevalence of LC, particularly among specific subgroups, with strong selection effects influencing outpatient participation. Differences in prevalence estimates emphasize the impact of case definitions and study designs on LC research. The identification of risk and protective factors supports targeted interventions and patient management strategies.</p><p><strong>Conclusion: </strong>This study provides one of the most comprehensive analyses of LC prevalence while accounting for selection bias. Our findings call for standardized LC definitions, improved epidemiological methodologies, and targeted prevention strategies. Future research should explore prospective cohorts to refine LC prevalence estimates and investigate long-term health outcomes.</p>","PeriodicalId":73083,"journal":{"name":"Frontiers in epidemiology","volume":"5 ","pages":"1597799"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12164371/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in epidemiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fepid.2025.1597799","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Long COVID (LC) is a multisystem condition with prolonged symptoms persisting beyond acute SARS-CoV-2 infection. However, prevalence estimates vary widely due to differences in case definitions and sampling methodologies. This study aims to determine the prevalence of LC across different definitions and correct for selection bias using advanced statistical modeling.

Methods: We conducted a retrospective, observational study at Luigi Sacco Hospital (Milan, Italy), analyzing 3,344 COVID-19 patients from two pandemic waves (2020-2021). Participants included 1,537 outpatients from the ARCOVID clinic and 1,807 hospitalized patients. LC was defined based on WHO and NICE criteria, as well as two alternative definitions: symptoms persisting at 3 and 6 months post-infection. We used a bivariate censored Probit model to account for selection bias and estimate adjusted LC prevalence.

Results: LC prevalence varied across definitions: 67.4% (WHO), 76.3% (NICE), 80.2% (3 months), and 79.6% (6 months). Adjusted prevalence estimates remained consistent across definitions. The most common symptoms were fatigue (58.6%), dyspnea (41.1%), and joint/muscle pain (39.2%). Risk factors included female sex (OR 2.165-2.379), metabolic disease (OR 1.587-1.629), and older age (40-50 years, OR 1.847). Protective factors included antiplatelets (OR 0.640-0.689), statins (OR 0.616), and hypoglycemics (OR 0.593-0.706). Vaccination, hydroxychloroquine, and antibiotics were associated with an increased risk of LC. Selection bias significantly influenced prevalence estimates, underscoring the need for robust statistical adjustments.

Discussion: Our findings highlight the high prevalence of LC, particularly among specific subgroups, with strong selection effects influencing outpatient participation. Differences in prevalence estimates emphasize the impact of case definitions and study designs on LC research. The identification of risk and protective factors supports targeted interventions and patient management strategies.

Conclusion: This study provides one of the most comprehensive analyses of LC prevalence while accounting for selection bias. Our findings call for standardized LC definitions, improved epidemiological methodologies, and targeted prevention strategies. Future research should explore prospective cohorts to refine LC prevalence estimates and investigate long-term health outcomes.

估算不同定义和样本选择形式的COVID-19长期流行率。
长冠肺炎(LC)是一种多系统疾病,其症状持续时间超过急性SARS-CoV-2感染。然而,由于病例定义和抽样方法的差异,患病率估计差异很大。本研究旨在确定LC在不同定义中的流行程度,并使用先进的统计建模来纠正选择偏差。方法:我们在意大利米兰的Luigi Sacco医院进行了一项回顾性观察研究,分析了两波(2020-2021年)的3344例COVID-19患者。参与者包括来自ARCOVID诊所的1537名门诊患者和1807名住院患者。LC的定义基于世卫组织和NICE标准,以及两种替代定义:感染后3个月和6个月症状持续。我们使用双变量删减Probit模型来解释选择偏差并估计调整后的LC患病率。结果:不同定义的LC患病率不同:67.4% (WHO), 76.3% (NICE), 80.2%(3个月)和79.6%(6个月)。调整后的患病率估计值在不同定义之间保持一致。最常见的症状是疲劳(58.6%)、呼吸困难(41.1%)和关节/肌肉疼痛(39.2%)。危险因素包括女性(OR为2.165-2.379)、代谢性疾病(OR为1.587-1.629)和年龄(40-50岁,OR为1.847)。保护因素包括抗血小板(OR 0.640-0.689)、他汀类药物(OR 0.616)和降糖药(OR 0.593-0.706)。疫苗接种、羟氯喹和抗生素与LC风险增加相关。选择偏差显著影响患病率估计,强调需要进行强有力的统计调整。讨论:我们的研究结果强调了LC的高患病率,特别是在特定的亚组中,有很强的选择效应影响门诊参与。患病率估计的差异强调了病例定义和研究设计对LC研究的影响。确定风险和保护因素有助于有针对性的干预措施和患者管理战略。结论:在考虑选择偏差的情况下,本研究提供了最全面的LC患病率分析之一。我们的研究结果呼吁标准化LC定义,改进流行病学方法和有针对性的预防策略。未来的研究应探索前瞻性队列,以完善LC患病率估计并调查长期健康结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信